Adare Pharma Solutions Coordinating Quality with Veeva Vault Quality Suite
The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.
Veeva Systems announced on Jan. 13, 2023 that Adare Pharma Solutions, a contract development and manufacturing (CDMO) with expertise in oral dosage forms, chose Veeva Vault Quality Suite to harmonize quality systems across the organization. This choice can help Adare streamline quality processes, work more effectively with partners and suppliers, and deliver greater visibility into operations to customers.
“As Adare expands its business, standardizing on the technology many of our customers use is a top priority to streamline collaboration,” said Audrey Butler, vice president, global head of quality at Adare Pharma Solutions, in a press release. “Veeva Vault Quality Suite will bring together our global teams on one platform for seamless processes and real-time data access that can help us improve how we work with clients and deliver differentiated services.”
The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy. Further, Adare will use Veeva Vault QMS to manage all quality processes, Veeva Vault QualityDocs to control documents and ensure quality, and Veeva Vault Training to drive employee qualifications. This new collaboration helps Adare to manage content, data, and training in a single end-to-end quality system.
“We’re proud to partner with Adare Pharma Solutions to help support their goals of improving services for clients and delivering transformational medicines for patients,” said Ashley Wentworth, senior director, Veeva Vault Quality strategy, in a press release. “With the Veeva Vault Quality Suite, Adare will have a scalable cloud platform that can keep up with evolving industry and customer requirements.”
Source: Adare Pharma Solutions
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
